Caladrius Biosciences, Inc.

Welcome to the Caladrius Biosciences first quarter 2021 financial results and business update conference call. Currently, all participants are in the listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by 1 on your touchtone phone. If anyone has difficulty hearing the conference call, please press star 0 for operator assistance. As a reminder, this call is being recorded today, Thursday, May 6, 2021. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

Thank you, Operator, and good afternoon, everyone. Welcome to Caladrius' first quarter 2021 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, and James Nisko, Vice President, Finance and Treasury. Earlier today, we issued a press release announcing our first quarter 2021 financial results, which is available under the Investors and News sections of our company website. If you have not received this news release, or if you would like to be added to the company's email distribution list, please email me at jmindido at colladrius.com. Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Caladrius. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-K, 10-Q, and 8-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statement. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, Thursday, May 6, 2021. Colleges Biosciences undertakes no obligation to revise or update statements to reflect events or circumstances after the date of this conference call. Please keep in mind that the company continues to conduct calls from different locations during the COVID-19 pandemic, so we appreciate your patience should we have any technical difficulties. With that, I will now turn the call over to Dr. Penn. Dave?

Thank you, John. Good afternoon, everyone, and thank you for joining us on today's call to discuss our first quarter 2021 financial results and recent business highlights. During the first quarter of 2021, we continued to advance our clinical development programs and strengthen our financial position, giving us the confidence and means to fund operations for the next several years based on our current development plans, while also allowing us to explore additional pipeline expansion opportunities. Over the last several months, we delivered on a number of strategic priorities in support of our robust autologous CD34 positive cell technology-based clinical pipeline, on which I will further expand in a few moments following the prepared remarks covering the financial results. With that, I will now turn the call over to James Nisko, our Vice President of Finance and Treasury, who will review and provide commentary on our quarterly financial results. James?